Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers, Start of Treatment, Specifications & Company Analysis – Global Forecast to 2022

ReportsWorldwide has announced the addition of a new report title Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers, Start of Treatment, Specifications & Company Analysis – Global Forecast to 2022 to its growing collection of premium market research reports. The continuing exploration of the benefits of proton therapy is inspiring […]

Advanced Oncotherapy (AVO)- Bracknor waives requirement to call a General Meeting

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that following discussions with the Company, Bracknor Investment Group has waived the requirement to call a General Meeting proposing a reduction in the nominal value of ordinary shares of 25p each, as had been stipulated in the Circular for the […]

Advanced Oncotherapy (AVO) – Holdings in company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may […]

Advanced Oncotherapy (AVO) – Harley Street construction update

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that excavation work at its flagship Harley Street site is progressing well and on time. Work has been completed on multiple stages of site work and demolition activity, with groundworks and piling, the longest stage in the excavation and build process […]

Advanced Oncotherapy (AVO) – Conversion of convertible loan notes

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the Convertible Loan Notes into new ordinary shares of 25p each in the share capital of the Company.  Further details of the conversion are set out […]

Advanced Oncotherapy (AVO) – Update on Bracknor financing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has drawn down the third tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche), for proceeds of £1.235 million.  Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, […]

Advanced Oncotherapy (AVO) – Conversion of loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the Convertible Loan Notes into new ordinary shares of 25p each in the share capital of the Company.  Further details of the conversion are set […]

Advanced Oncotherapy (AVO) – Holdings in company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may […]